Integrated data analysis results indicated that ustekinumab-treated patients ( regardless of dose ) demonstrated significantly less radiographic progression at wk 24 than did placebo recipients ( wk 0-24 total vdH-S score mean changes : 0.4-combined / individual ustekinumab dose groups , 1.0-placebo ; all p < 0.02 ) .